Corporate Philanthropy - Best Practices at Novartis AG

Case Studies | Case Study in Business, Management, Operations, Strategy, Case Study

ICMR HOME | Case Studies Collection

Case Details:

Case Code : BECG063
Case Length : 23 Pages
Period : 2000-06
Organization : Novartis AG, Novartis Foundation for Sustainable
Pub Date : 2006
Teaching Note : Available
Countries : Switzerland
Industry : Pharmaceutical

To download Corporate Philanthropy - Best Practices at Novartis AG case study (Case Code: BECG063) click on the button below, and select the case from the list of available cases:


For delivery in electronic format: Rs. 500 ;
For delivery through courier (within India): Rs. 500 + Rs. 25 for Shipping & Handling Charges

Business Ethics Case Studies
Case Studies Collection
View Detailed Pricing Info
How To Order This Case
Business Case Studies
Case Studies by Area
Case Studies by Industry
Case Studies by Company

Please note:

This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.

<< Previous


Background Note

Novartis was the result of a merger between Ciba-Geigy and Sandoz in 1996. The origins of Geigy could be traced back to 1758, when Johann Rudolf Geigy-Gemuseus started a company that traded in materials, chemicals, dyes, and drugs in Basel, Switzerland...

About Novartis Foundation

The origin of the Novartis Foundation can be traced back to the year 1979. At that time, it was known as the Ciba-Geigy Foundation for Cooperation with Developing Countries (Ciba-Geigy Foundation). The Foundation was formed to help Third World countries fight against health and poverty related problems. It was particularly active in the areas of leprosy and TB. After the formation of Novartis, the Foundation was renamed as the Novartis Foundation for Sustainable Development. The Novartis Foundation acted as a link between the company and the community. It communicated the happenings in the external world to the management of Novartis.

Novartis Corporate Citizenship Initiative

The UN secretary general, Kofi Annan, proposed the Global Compact in an address to the World Economic Forum in 1999. The Global Compact had nine principles drawn from the Universal Declaration of Human Rights 1948 , the International Labour Office (ILO) Declaration on Fundamental Principles of Rights at Work, 1988 , and the Rio Principles on Environment and Development, 1992...

Tackling Leprosy

The WHO had recommended Multidrug Therapy (MDT) to treat leprosy . Two of the drugs used in MDT, clofazimine and rifampicin were developed by Novartis. Since the year 1995, Novartis had been providing MDT for leprosy patients and was one of the two suppliers providing leprosy drugs to the WHO. From 1998, MDT was sourced exclusively from Novartis. In 1999, the Global Alliance for Elimination of Leprosy was formed at the initiative of the WHO. The members in the alliance were the WHO, leprosy endemic countries , the International Federation of Anti Leprosy Associations, the Nippon/Sasakawa Memorial Health Foundation, and Novartis...

Fighting Against Tuberculosis

According to WHO estimates, as of 2004, TB killed around two million people every year across the world. Around eight million people developed TB every year. In 1993, the WHO declared TB as a global emergency...

Excerpts Contd...>>


Case Studies Links:- Case Studies, Short Case Studies, Simplified Case Studies.

Other Case Studies:- Multimedia Case Studies, Cases in Other Languages.

Business Reports Link:- Business Reports.

Books:- Textbooks, Work Books, Case Study Volumes.